Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study.

Blood Adv · 2026 · PMC13194599 · PMID 41785311

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

There was a clear trend of increasing exposure with increasing dose for both selinexor and ruxolitinib ( supplemental Figure 9 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.